Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
Leonora W. de Boo(The Netherlands Cancer Institute), Sabine C. Linn(Oncode Institute), Susanna Lauttia(University of Helsinki), Philip C. Schouten(Cambridge University Hospitals NHS Foundation Trust), Michael Hauptmann(Medizinische Hochschule Brandenburg Theodor Fontane), Henrik Lindman(Uppsala University), Roelof J.C. Kluin(The Netherlands Cancer Institute), Marleen Kok(The Netherlands Cancer Institute), Petra M. Nederlof(The Netherlands Cancer Institute), Charlaine van Steenis(The Netherlands Cancer Institute), Wim Brugman(The Netherlands Cancer Institute), Mark Opdam(The Netherlands Cancer Institute), Heikki Joensuu(Orion Corporation (Finland)), Katarzyna Jóźwiak(The Netherlands Cancer Institute)
Cited by 41
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k